May 12, 2020 / 5:07 AM / 17 days ago

BRIEF-Idorsia: Neurocrine Biosciences Exercises Option To License Idorsia's Novel Treatment For Rare Pediatric Epilepsy

May 12 (Reuters) - Idorsia Ltd:

* NEUROCRINE BIOSCIENCES EXERCISES OPTION TO LICENSE IDORSIA’S NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

* IDORSIA RECEIVES A $45 MILLION UPFRONT PAYMENT IN CASH.

* WILL ALSO BE ENTITLED TO POTENTIAL DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS UP TO $365 MILLION AND TIERED ROYALTIES ON NET SALES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below